

This past Wednesday, September 9, we had such an informative and well-presented session on clonal sequencing and minimal residual disease, presented by Dr Christina Spencer, from Adaptive Biotechnologies. The in depth but easy to follow and understand presentation clarified the significance of this specific testing for myeloma patients. Adaptive's next generation sequencing (NGS) is unique in assessing the DNA and profile of a patient that ultimately allows for the patient and their medical team to chart a proper and very specific treatment course.

We had a great turnout of 38 members attending that were all impressed with the information and prepared for an insightful discussion with their specialists on this topic, when necessary.

We sincerely appreciate Dr. Spencer and the Adaptive Biotechnologies team supporting us and the entire myeloma community. Bringing innovation and advances that make a meaningful impact in all of our lives!

Next Virtual Meeting - October 7, 2026. 6:30 pm.

Guest Speaker - Tom Whitehead. Co-founder of the Emily Whitehead Foundation.

Tom Whitehead's daughter, Emily, was the first child in the world whose cancer was cured with CAR-T cell therapy.

The significance of this meeting is that Emily and her family's courage, paved the way for the advances in CAR-T treatment today that impact not only multiple myeloma, but virtually dozens of other cancers.